References

A global consensus on the classification, diagnosis, and multidisciplinary treatment of perianal fistulising Crohn’s disease

10.1136/gutjnl-2013-306709 · 2014 · External reference

3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: Part 1: diagnosis and medical management

10.1093/ecco-jcc/jjw168 · 2017 · External reference

The characteristics and long-term outcomes of pediatric Crohn’s disease patients with perianal disease

10.1097/mib.0000000000001171 · 2017 · External reference

Perianal pediatric Crohn disease is associated with a distinct phenotype and greater inflammatory burden

10.1097/mpg.0000000000001484 · 2017 · External reference

Diagnosis and clinical features of perianal lesions in newly diagnosed Crohn’s disease: subgroup analysis from inception cohort registry study of patients with Crohn’s disease (iCREST-CD)

10.1093/ecco-jcc/jjad038 · 2023 · External reference

Predictors of Crohn’s disease

10.1053/j.gastro.2005.12.019 · 2006 · External reference

Perianal disease onset age is associated with distinct disease features and need for intestinal resection in perianal Crohn’s disease: a ten-year hospital-based observational study in China

10.1186/s12876-021-01961-9 · 2021 · External reference

ECCO guidelines on therapeutics in Crohn’s disease: medical treatment

10.1093/ecco-jcc/jjae091 · 2024 · External reference

ECCO guidelines on therapeutics in Crohn’s disease: surgical treatment

10.1093/ecco-jcc/jjae089 · 2024 · External reference

The medical management of paediatric Crohn’s disease: an ECCO-ESPGHAN guideline update

10.1093/ecco-jcc/jjaa161 · 2021 · External reference

Significant medical and surgical morbidity in perianal Crohn’s disease: results from a territory-wide study

10.1093/ecco-jcc/jjy120 · 2018 · External reference

Ustekinumab use in pediatric inflammatory bowel disease: a French multicenter study from the pediatric GETAID

10.1097/mpg.0000000000003758 · 2023 · External reference

Safety and effectiveness of ustekinumab for Crohn’s disease with perianal manifestations: ad hoc analysis data from 1-year post-marketing surveillance study in Japan

10.1093/crocol/otae035 · 2024 · External reference

Ustekinumab for perianal Crohn’s disease: the biolap multicenter study from the GETAID

10.14309/ajg.0000000000000810 · 2020 · External reference

Ustekinumab is effective for perianal fistulising Crohn’s disease: a real-world experience and systematic review with meta-analysis

10.1136/bmjgast-2021-000702 · 2021 · External reference

Ustekinumab promotes radiological fistula healing in perianal fistulizing Crohn’s disease: a retrospective real-world analysis

10.3390/jcm12030939 · 2023 · External reference

Management of paediatric patients with medically refractory Crohn’s disease using ustekinumab: a multi-centred cohort study

10.1093/ecco-jcc/jjy206 · 2019 · External reference

Real world experience with ustekinumab in children and young adults at a tertiary care pediatric inflammatory bowel disease center

10.1097/mpg.0000000000002362 · 2019 · External reference

Safety and potential efficacy of escalating dose of ustekinumab in pediatric Crohn disease (the speed-up study): a multicenter study from the Pediatric IBD Porto group of ESPGHAN

10.1097/mpg.0000000000003608 · 2022 · External reference

Ustekinumab in paediatric patients with moderately to severely active Crohn’s disease: pharmacokinetics, safety, and efficacy results from UniStar, a phase 1 study

10.1093/ecco-jcc/jjab089 · 2021 · External reference

Development and validation of a pediatric MRI-based perianal Crohn disease (PEMPAC) index-a report from the ImageKids study

10.1093/ibd/izab147 · 2022 · External reference

ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents

10.1097/mpg.0000000000000239 · 2014 · External reference

Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification

10.1002/ibd.21493 · 2011 · External reference

Mathematical weighting of the pediatric Crohn’s disease activity index (PCDAI) and comparison with its other short versions

10.1002/ibd.21649 · 2012 · External reference

Infliximab for the treatment of fistulas in patients with Crohn’s disease

10.1056/nejm199905063401804 · 1999 · External reference

Assessing the activity of perianal Crohn’s disease: comparison of clinical indices and computer-assisted anal ultrasound

10.1002/ibd.20826 · 2009 · External reference

Ustekinumab induction and maintenance therapy in refractory Crohn’s disease

10.1056/nejmoa1203572 · 2012 · External reference

Ustekinumab for the treatment of refractory Crohn’s disease: the Spanish experience in a large multicentre open-label cohort

10.1097/mib.0000000000000842 · 2016 · External reference

Long-term effects of ustekinumab in children with inflammatory bowel disease: a systematic review

10.1002/jpn3.70163 · 2025 · External reference

Efficacy of ustekinumab for active perianal fistulizing Crohn’s disease: a systematic review and meta-analysis of the current literature

10.1080/00365521.2020.1854848 · 2021 · External reference

STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD

10.1053/j.gastro.2020.12.031 · 2021 · External reference

Effectiveness of reinduction and/or dose escalation of ustekinumab in Crohn’s disease: a systematic review and meta-analysis

10.1016/j.cgh.2021.10.002 · 2022 · External reference

Ustekinumab is safe and effective in pediatric patients with Crohn’s disease

10.1002/jpn3.12452 · 2025 · External reference

ACG clinical guideline: management of Crohn’s disease in adults

10.14309/ajg.0000000000003465 · 2025 · External reference

Higher ustekinumab levels in maintenance therapy are associated with greater mucosal healing and mucosal response in Crohn’s disease: an experience of 2 IBD centers

10.1093/ibd/izad073 · 2024 · External reference

Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn’s disease

10.1016/s0002-9270(02)05909-9 · 2003 · External reference

Shorter disease duration is associated with higher rates of response to vedolizumab in patients with Crohn’s disease but not ulcerative colitis

10.1016/j.cgh.2018.12.040 · 2019 · External reference

Endoscopic activity and serum TNF-α level at baseline are associated with clinical response to ustekinumab in Crohn’s disease patients

10.1093/ibd/izaa086 · 2020 · External reference

Effectiveness and safety of ustekinumab in inflammatory bowel disease: a systematic review and meta-analysis

10.1007/s10620-021-06932-4 · 2022 · External reference

Effectiveness and safety of ustekinumab for pediatric inflammatory bowel disease: a systematic review

10.1007/s40272-023-00586-7 · 2023 · External reference